Celecoxib builds up and cues metabolically active bacteria inhabiting the mucosal environment of a simulated human intestinal ecosystem, modulating inflammatory response. Long-term faecal incubations

This study aimed at elucidating how this birectional flow impacts the functional and taxonomical features of the gut microbiome and the anti-inflammatory potency of celecoxib (a COX-2 inhibitor). We developed an in vitro platform to explore the interface between microbiome, mucus layer and epithelium, coupling a dynamic gut model with a cell model to mimic the intestinal metabolism of a colon-targeted celecoxib formulation. Long-term monitoring of a clinical dose of celecoxib was performed using the Mucosal Simulator of the Human Intestinal Microbial Ecosystem (M-SHIME)